CLClémence Lacroix

Clémence Lacroix

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Clémence Lacroix has a total of 40 co-authors. Here are the top co-authors by number of shared publications:

  • Joëlle Micallef

    Ctr Evaluat & Informat Pharmacodependance Addictov, PACA Corse, Serv Pharmacol Clin & Pharmacovigilance, AP HM St Marguerite,AMU,INS,Inserm,UMR1106, F-13000 Marseille, France

    7 shared publications
  • Elisabeth Jouve

    Service de Pharmacologie Clinique et Pharmacosurveillance, Centre d’évaluation et d’information sur la pharmacodépendance – Addictovigilance Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, UMR 1106, University Hospital, Marseille, France

    5 shared publications
  • Joëlle Micallef

    The Institut de Neurosciences des Systèmes INS, UMR1106, Aix Marseille University, Marseille, France

    5 shared publications
  • Elisabeth Jouve

    AMU, AP HM St Marguer, Ctr Evaluat & Informat Pharmacodependance Addictov, Serv Pharmacol Clin & Pharmacosurveillance,INS,Ins, F-13000 Marseille, France

    4 shared publications
  • Thomas Soeiro

    Service de Pharmacologie Clinique et Pharmacosurveillance, Centre d’évaluation et d’information sur la pharmacodépendance – Addictovigilance Aix Marseille Univ, APHM, INSERM, Inst Neurosci Syst, UMR 1106, University Hospital, Marseille, France

    4 shared publications
  • Clément Garnier

    AMU, AP HM St Marguer, Ctr Evaluat & Informat Pharmacodependance Addictov, Serv Pharmacol Clin & Pharmacosurveillance,INS,Ins, F-13000 Marseille, France

    3 shared publications

Latest Publications

  • Open Access

    Factors Associated With Cocaine Use Disorder: Results From the French Nationwide Repeated Cross‐Sectional OPPIDUM Study (2019–2023)

    by Zenab Alhamidi, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Céline Eiden, Joëlle Micallef

    Cocaine use has increased both globally and nationally. This trend is accompanied by a rise in clinical complications. The objective of our study was to identify factors observed to be associated with cocaine use disorder, using data from the OPPIDUM program, collecting information directly from patients with substance use disorders recruiting in care or harm reduction facilities. Cocaine users were divided into two groups: cocaine use disorder and simple use. A univariate analysis was performed to compare the groups, followed by a multivariate analysis to identify factors associated with cocaine use disorder. Between 2019 and 2023, 6863 cocaine users (28% of all OPPIDUM participants) from 116 addiction treatment centers were included. Several factors were found to be significantly associated with cocaine use disorder: extreme precariousness (OR = 1.34, 95% CI [1.12–1.61], p = 0.002), cocaine‐only use (OR = 1.90, 95% CI [1.45–2.50], p < 0.0001), alcohol dependence (OR = 1.48, 95% CI [1.30–1.68], p < 0.0001), and use of antidepressants and antipsychotics (OR = 2.08, 95% CI [1.37–3.16], p = 0.001; OR = 1.94, 95% CI [1.40–2.69], p < 0.001). These findings highlight several key factors associated with cocaine use disorder and their clinical implications. The study has limitations: potential selection bias, repeated inclusion of the same users across years, multiple modes of cocaine use, and the exploratory nature of the analyses due to uncontrolled alpha risk. Nevertheless, these insights can help healthcare professionals better understand patient profiles and provide more tailored care and prevention strategies.

  • Open Access

    Use of Psychoactive Substances Before Incarceration Among Prison Inmates With Drug Abuse or Dependence: Data From the OPPIDUM Program

    by Zeinab Abbas, Clémence Lacroix, Elisabeth Jouve, Céline Eiden, Joelle Micallef, Hélène Peyrière, The French Addictovigilance Network

    Background: The objective of this study was to assess the prevalence of dependence and abuse of psychoactive substances (PAS) among prison inmates, using data from the OPPIDUM program between 2013 and 2022. Methods: OPPIDUM is an annual, cross‐sectional national program, conducted among users consulting in specialised addiction centres. Prison inmates were questioned about their PAS use during the week preceding their incarceration. Two groups of participants were compared: prison inmates who reported simple use of PAS and those with abuse/dependence problems. Results: A total of 2626 individuals responded to the program (men, 91.6%; mean age, 34.4 ± 9.30 years), reporting 5352 PAS. The main PAS consumed were cannabis (52.8%), cocaine/crack (28.6%), benzodiazepines (23.1%) and heroin (14.8%). Opioid substitution treatment (OST) was reported by 54.9% of participants. Several variables were associated with a significantly increased odds of abuse/dependence: intravenous use (OR, 4.608; 95% CI, 1.44–14.69; p = 0.01), PAS illegal acquisition (OR, 3.79; 95% CI, 2.19–6.58; p < 0.0001), heroin/speedball use (OR, 4.24; 95% CI, 1.16–15.48; p = 0.029) and cocaine/crack use (OR, 3.3; 95% CI, 1.47–7.39; p = 0.004). Conversely, being on OST protocol was associated with a lower odds of abuse/dependence (OR, 0.511; 95% CI, 0.28–0.93; p = 0.028). Limitations and Conclusion: The main limitations of the study include self‐reported PAS use without objective diagnoses, sometimes incomplete data on PAS use and incarceration and a sample biased toward inmates linked to substance abuse services, which likely overestimates the prevalence of PAS use. However, these results highlight the importance of assessing factors associated with substance abuse and dependence for appropriate prevention and management among prison inmates.

  • Open Access

    Psychoactive prescription drug use and misuse in patients on opioid agonist treatment

    by Thomas Soeiro, Clémence Lacroix, Élisabeth Jouve, Élisabeth Frauger, Maryse Lapeyre‐Mestre, Joëlle Micallef

    Aims: To identify the patterns and trends in prescription drug use and misuse in patients on opioid agonist treatment. Methods: We used data from the OPPIDUM programme, which collects data from patients attending substance abuse treatment facilities. Data collected include use of psychoactive prescription drugs in the past week. In this cross‐sectional study, we included patients aged at least 18 years, on opioid agonist treatment and reporting psychoactive prescription drug use in the past week from 2014 to 2023. The outcome was psychoactive prescription drug misuse (i.e., abuse and/or dependence, illegal acquisition and diverted route of administration) in the past week. We conducted disproportionality analyses to identify prescription drugs associated with misuse. We calculated the prevalence of use and misuse for each prescription drug to estimate trends. Results: We included 9631 patients. Misuse was disproportionately reported for morphine (e.g., diverted route of administration: n = 580; reporting odds ratio: 224.4 [95% confidence interval: 178.8, 281.7]), methylphenidate (e.g., diverted route of administration: 149; 31.6 [24.1, 41.4]), oxycodone (e.g., diverted route of administration: 24; 20.2 [11.1, 36.8]), clonazepam (e.g., illegal acquisition: 48; 6.0 [4.0, 9.0]) and fentanyl (e.g., diverted route of administration: 6; 5.8 [2.3, 14.8]). Trends in misuse paralleled trends in use for most prescription drugs. The sharpest increase in misuse included abuse and/or dependence (+2366%, from 0.9 per 1000 patients in 2014 to 23.0 per 1000 patients in 2023) for pregabalin. Conversely, the sharpest decrease in misuse included illegal acquisition (−59%, from 82.1 per 1000 patients in 2014 to 33.9 per 1000 patients in 2023) for morphine. Conclusion: In this population, prescription drug misuse primarily included opioid analgesics and increasingly pregabalin. Given the risk of opioid overdose, access to take‐home naloxone should be further improved.

  • Évolution du profil d’usagers de prégabaline dans les centres spécialisés en addictologie à partir des résultats de l’enquête OPPIDUM (2008–2022)

    by Clémence Lacroix, Clément Garnier, Martin Schein, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre-Mestre, Joëlle Micallef

  • Open Access

    Monitoring misuse and abuse of psychoactive substances in France: Insights from substance abuse treatment facilities through the OPPIDUM program

    by Clémence Lacroix, Elisabeth Frauger, Elisabeth Jouve, Hélène Peyrière, Joëlle Micallef


  • Open Access

    Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

    by Clément Garnier, Martin Schein, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre-Mestre, Joëlle Micallef

  • Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

    by Clément Garnier, Martin Schein, Clémence Lacroix, Elisabeth Jouve, Thomas Soeiro, Gaétan Gentile, Maryse Lapeyre Mestre, Joëlle Micallef

    Introduction In recent years, pregabalin has received growing attention due to its abuse liability. The aim of this study was to further characterize patterns of pregabalin users from substance abuse treatment facilities and detect changes in users profile over the study period. Methods The data source was the Observation des Produits Psychotropes Illicites ou Détournés de leur Utilisation Médicamenteuse (OPPIDUM) program, an annual, repeated, cross-sectional, nationwide, multicenter survey that collects consumption data from patients with substance use disorders. First, we described the characteristics of pregabalin users and their consumption patterns. We compared these data between 2008 and 2018 (P1) and 2019 and 2022 (P2). Second, we conducted a multiple correspondence analysis to identify profiles of users. Results From 2008 to 2022, 291 pregabalin users (0.37% of all users) from 116 substance abuse treatment facilities were identified. The number of pregabalin users was lower than 15 per year in P1 (n = 89) and between 40 and 60 per year in P2 (n = 202). The number of users who reported pregabalin as the first substance leading to dependence increased significantly in P2 compared with P1 (p < 0.005). When comparing P2 with P1, there was a significant increase in precarity (p < 0.001), users in prison (p = 0.002), withdrawal symptoms (p < 0.001), dependence (p < 0.001), use of higher dose of pregabalin (p = 0.029), and acquisition by deal/street market (p < 0.001). The multiple correspondence analysis allowed for the identification of distinct profiles of pregabalin users: (i) a cluster with mainly users from P1, who presented a simple use of pregabalin, and were older (> 45 years), were involved in opioid agonist treatment (OAT), and obtained pregabalin legally; and (ii) a cluster with mainly users from P2, who presented pregabalin dependence, and were younger (< 26 years), reported pregabalin as the first substance leading to dependence, used doses higher than the market authorization, were in severe precarity, and were in prison. Conclusions These data showed that the profile of pregabalin users has changed in the last years. Pregabalin use disorders also affect users without history of addiction.


  • Cannabis for the treatment of amyotrophic lateral sclerosis: What is the patients’ view?

    by C. Lacroix, R. Guilhaumou, J. Micallef, G. Bruneteau, C. Desnuelle, O. Blin


  • Cannabidiol and pharmacokinetics drug-drug interactions: Pharmacological toolbox

    by Clémence Lacroix, Romain Guilhaumou, Joëlle Micallef, Olivier Blin